Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $17
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $20 to $17.